Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MACROGENICS, INC.

(MGNX)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

MACROGENICS INC : Change in Directors or Principal Officers (form 8-K)

09/27/2021 | 04:14pm EST
Item 5.02            Departure of Directors or Certain Officers; Election of Directors;
                     Appointment of Certain Officers; Compensatory Arrangements of Certain
                     Officers.


On September 23, 2021, Mr. Paulo Costa, a member of the board of directors (the "Board") of MacroGenics, Inc. (the "Company"), notified the Board that he will not stand for reelection as a director of the Company upon expiration of his current term. Mr. Costa's term expires at the Company's 2022 annual meeting of stockholders (the "2022 Annual Meeting"). Mr. Costa is currently Chair of the Board and Chair of the Nominating and Governance Committee, and will serve in his current positions until the conclusion of the 2022 Annual Meeting.

Mr. Costa's decision to let his term expire and not to stand for reelection at the 2022 Annual Meeting is for personal reasons and not based on any disagreement with the Company or its management. He has served on the Company's Board of Directors since June 2009.

© Edgar Online, source Glimpses

All news about MACROGENICS, INC.
11/17Guggenheim Assumes MacroGenics at Buy with $30 Price Target
MT
11/03MacroGenics to Participate in Upcoming Investor Conferences
GL
11/03Wedbush Trims MacroGenics' Price Target to $30 From $32, Keeps Outperform Rating
MT
11/02MacroGenics Provides Update on Corporate Progress and Third Quarter 2021 Financial Resu..
PU
11/02MACROGENICS : Q3 Earnings Snapshot
AQ
11/02MACROGENICS INC MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULT..
AQ
11/02Earnings Flash (MGNX) MACROGENICS Posts Q3 Revenue $15.7M
MT
11/02MacroGenics Provides Update on Corporate Progress and Third Quarter 2021 Financial Resu..
AQ
11/02MacroGenics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended ..
CI
10/26MacroGenics Announces Date of Third Quarter 2021 Financial Results Conference Call
AQ
More news
Analyst Recommendations on MACROGENICS, INC.
More recommendations
Financials (USD)
Sales 2021 84,7 M - -
Net income 2021 -194 M - -
Net Debt 2021 - - -
P/E ratio 2021 -5,51x
Yield 2021 -
Capitalization 1 097 M 1 097 M -
Capi. / Sales 2021 13,0x
Capi. / Sales 2022 8,93x
Nbr of Employees 370
Free-Float 93,9%
Chart MACROGENICS, INC.
Duration : Period :
MacroGenics, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MACROGENICS, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 11
Last Close Price 17,91 $
Average target price 36,78 $
Spread / Average Target 105%
EPS Revisions
Managers and Directors
Scott E. Koenig President, Chief Executive Officer & Director
James Karrels Chief Financial Officer, Secretary & Senior VP
Paulo F. Costa Chairman
Ezio Bonvini Chief Scientific Officer & Senior VP-Research
Stephen L. Eck Chief Medical Officer & SVP-Clinical Development
Sector and Competitors
1st jan.Capi. (M$)
MACROGENICS, INC.-21.65%1 150
GILEAD SCIENCES, INC.20.61%88 146
BIONTECH SE326.89%84 049
REGENERON PHARMACEUTICALS33.17%67 266
WUXI APPTEC CO., LTD.27.38%64 416
VERTEX PHARMACEUTICALS-22.32%46 678